Erbulozole

Erbulozole

SCHEMBL3824

CCOC(=O)Nc1ccc(SC[C@H]2CO[C@](Cn3ccnc3)(c3ccc(OC)cc3)O2)cc1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 8/20 0.40
CYP19A1 P11511 5/20 0.40
CYP17A1 P05093 4/20 0.40
CYP11B1 P15538 3/20 0.40
CYP51A1 Q16850 2/20 0.40
CYP21A2 P08686 3/20 0.40
USP2 O75604 2/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
MEN1 O00255 1/20 0.40
SLC22A1 O15245 1/20 0.40
ABCC4 O15439 1/20 0.40
CYP27B1 O15528 1/20 0.40
CYP26A1 O43174 1/20 0.40
NR1I2 O75469 1/20 0.40
GMNN O75496 1/20 0.40
ABCB11 O95342 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Erbulozole SCHEMBL9488172 1.00 CYP3A4 (0.40) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
Erbulozole SCHEMBL9488166 1.00 CYP3A4 (0.40) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
Erbulozole SCHEMBL27849451 0.99 CYP3A4 (0.40) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
SCHEMBL9488205 0.92 CYP3A4 (0.42) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
SCHEMBL9488211 0.92 CYP3A4 (0.42) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
SCHEMBL9490358 0.92 CYP3A4 (0.42) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
SCHEMBL9489826 0.92 CYP3A4 (0.42) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
SCHEMBL9488791 0.92 TBXAS1 (0.43) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
SCHEMBL9490323 0.92 CYP3A4 (0.39) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1
SCHEMBL9488796 0.92 TBXAS1 (0.43) CYP3A4CYP19A1CYP17A1CYP11B1CYP51A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 9795 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
EP-4524131-A1 SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH AlonBio Ltd. (IL) 2025-03-19 EP claimed
US-12202803-B2 Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death ALONBIO LTD. (IL) 2025-01-21 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-12109219-B2 Cannabinoid receptor modulators ARENA PHARMACEUTICALS, INC. (US) 2024-10-08 US claimed
WO-2024162488-A1 PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN 주식회사 재인알앤피 2024-08-08 WO claimed
EP-4401780-A1 AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF University of Maryland, College Park (US) 2024-07-24 EP claimed
US-20240002347-A1 SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH ALONBIO LTD. (IL) 2024-01-04 US claimed
WO-2023044436-A1 AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2023-03-23 WO claimed
WO-2007059116-A2 GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF ABRAXIS BIOSCIENCE, INC. (US) 2007-05-24 WO claimed
US-20060142393-A1 Bis(thio-hydrazide amides) for treatment of hyperplasia SYNTA PHARMACEUTICALS CORP. 2006-06-29 US claimed
US-20060079472-A1 Methods for treating angiogenesis ANGIOSYN, INC. 2006-04-13 US claimed
WO-2006033913-A2 BIS (THIO-HYDRAZIDE AMIDES) FOR TREAMENT OF HYPERPLASIA SYNTA PHARMACEUTICALS CORP. (US) 2006-03-30 WO claimed
US-20060024365-A1 Novel dosage form VAYA NAVIN 2006-02-02 US claimed
US-20060018933-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20060018934-A1 Novel drug delivery system TORRENT PHARMACEUTICALS LIMITED (IN) 2006-01-26 US claimed
US-20040092583-A1 Treatment for inhibiting neoplastic lesions SHANAHAN-PRENDERGAST ELIZABETH (IE) 2004-05-13 US claimed
EP-1351678-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS Shanahan-Prendergast, Elizabeth (IE) 2003-10-15 EP claimed
WO-2002053138-A2 TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS SHANAHAN-PRENDERGAST ELISABETH (IE) 2002-07-11 WO claimed